Exelixis (EXEL)
(Delayed Data from NSDQ)
$26.46 USD
+0.15 (0.57%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $26.44 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.46 USD
+0.15 (0.57%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $26.44 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) reported a narrower-than-expected loss in Q2 on the back of higher Ocaliva sales.
ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up
by Zacks Equity Research
ImmunoGen's (IMGN) Q2 results report a narrower-than-expected loss with revenue beating the estimates. The company also significantly raises the cash and revenue guidance this quarter.
Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise
by Zacks Equity Research
Dr. Reddy's Laboratories Ltd.'s (RDY) first-quarter fiscal 2018 earnings per American Depositary Share (ADS) declined year over year while sales increased from the year ago quarter.
Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line
by Zacks Equity Research
Acorda's (ACOR) dismal performance in Q2 significantly misses earnings expectations. However, the company's revenues met estimates on the back of strong Ampyra sales.
Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat
by Zacks Equity Research
Keryx's (KERX) loss in Q2 was wider than expected but sales beat estimates. The company also raised its 2017 outlook for net U.S. Auryxia product sales.
Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Alkermes plc (ALKS) incurred narrower than expected loss in Q2 but marginally surpassed sales estimates. The company reiterated its 2017 outlook.
Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View
by Zacks Equity Research
Celgene Corporation (CELG) beat earnings and revenue estimates in the second quarter and upped view.
GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance
by Zacks Equity Research
Glaxo's (GSK) second-quarter earnings beat estimates, while revenues miss the same. The company cuts its core 2017 earnings growth at CER, with no Advair generics launched this year.
Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) exceeded both earnings and revenue estimates in Q2 and also raised its 2017 guidance.
Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up
by Zacks Equity Research
Gilead Sciences' (GILD) better-than-expected second-quarter results boosted investors sentiments.
What's in the Cards for Exelixis (EXEL) in Q2 Earnings?
by Zacks Equity Research
Exelixis, Inc.'s (EXEL) efforts to develop its pipeline and uptake in Cabometyx sales should be the key areas of focus when the company reports second-quarter results.
Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab
by Zacks Equity Research
Emergent's shares inched up post announcement of its deal inked with GlaxoSmithKline to acquire the latter's anthrax monoclonal antibody raxibacumab.
Vertex (VRTX) Triple Combination CF Studies Data Positive
by Zacks Equity Research
Vertex announced positive data from three studies evaluating three different triple combination regimens. These demonstrated pronounced improvements in lung function in CF patients.
Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt
by Zacks Equity Research
Valeant (VRX) has decided to sell Obagi Medical for $190 million and use the proceeds for reducing down debt.
Agenus (AGEN) Catches Eye: Stock Moves Up 8.7% in Session
by Zacks Equity Research
Agenus Inc. (AGEN) moved big last session, as its shares rose over 8% on the day.
Arena Announces Secondary Stock Worth $150M (revised)
by Zacks Equity Research
Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions.
Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
by Zacks Equity Research
Emergent BioSolutions Inc. (EBS) announced that it has inked an agreement to acquire the FDA-licensed smallpox vaccine's business of Sanofi (SNY) in an all-cash deal of up to $125 million.
Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?
by Zacks Equity Research
Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company's shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized industry during this period.
BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) announced an exclusive partnership agreement with Purdue Pharma, a Canadian pharmaceutical company, for commercializing its pain drug Belbuca in Canada.
Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform
by Zacks Equity Research
We issued an updated research report Endocyte, Inc. (ECYT) on Jul 12.
Why Exelixis (EXEL) Could Be an Impressive Growth Stock
by Zacks Equity Research
Exelixis (EXEL) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Arena Announces Secondary Stock Offering of 150M Shares
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) plans to offer and sell 150 million shares of its common stock, subject to customary closing conditions.
Five Scorching Hot Stocks Screaming Higher
by David Bartosiak
Five Zacks Rank #1 (Strong Buy) stocks at 52-week highs pushing even higher
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
by Zacks Equity Research
Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC.
The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners